{"url_path":"/sec/hcwb/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-023122-index.html","accession_number":"0001493152-26-023122","cik":"0001828673","ticker":"HCWB","issuer_name":"HCW Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-023122-index.html","primary_entity_key":"0001828673","primary_entity_name":"HCW Biologics Inc."},"word_count":145,"has_tables":true,"body_markdown":"** **\n\n**Item\n2.02 Results of Operations and Financial Condition.**\n\n \n\nOn\nMay 14, 2026, HCW Biologics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.\nThe full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on\nForm 8-K.\n\n \n\nThe\ninformation set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the\nExchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in\nsuch a filing."}